Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan-Dec:37:15333175221124952.
doi: 10.1177/15333175221124952.

The Association Between Dextromethorphan Use and the Risk of Dementia

Chia-Yuan Chen  1 , Chi-Hsiang Chung  2   3 , Wu-Chien Chien  2   3 , Hsin-Chien Chen  1
Affiliations

The Association Between Dextromethorphan Use and the Risk of Dementia

Chia-Yuan Chen et al. Am J Alzheimers Dis Other Demen. 2022 Jan-Dec.

Abstract

Dementia is one of neurodegenerative disease without preventive medicine currently. Dextromethorphan (DXM) has been reported to reduce neuronal damage and neurodegeneration in animal and human models. The effect of DXM on the dementia has not been fully examined. We examined the medical records over 40 years old in Taiwan's National Health Insurance Research Database between 2000 and 2015 to establish matched cohorts. We used a Cox regression hazard model to identify risk factors of dementia during 16 years of follow-up, and the results indicate that a significantly lower percentage of subjects with DXM use (P < .001) developed dementia compared with those without DXM use (11.38%, 4541/39 895 vs 18.66%, 29 785/159 580). After adjustment for age and other variables [adjusted hazard ratio: .567 (95% confidence interval: .413-.678, P < .001)], this study also demonstrated that DXM use appeared to reduce the risk of developing dementia. DXM use may potentially provide a protective effect against dementia.

Keywords: Alzheimer disease; cognition decline; dementia; dextromethorphan.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
The flowchart of study sample selection.
Figure 2.
Figure 2.
Kaplan-Meier for cumulative risk of dementia among aged 40 and over stratified by dextromethorphan with log-rank test.
See this image and copyright information in PMC

References

    1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3:186-191. - PubMed
    1. World Health Organization. Dementia . https://www.who.int/news-room/fact-sheets/detail/dementia2/Sep/2021
    1. Werling LL, Lauterbach EC, Calef U. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist. 2007;13:272-293. - PubMed
    1. Hernandez SC, Bertolino M, Xiao Y, Pringle KE, Caruso FS, Kellar KJ. Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors. J Pharmacol Exp Ther. 2000;293:962-967. - PubMed
    1. Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacology & Therapeutics. 2016;164:170-182. - PubMed

Publication types

Substances